Deloitte
Accounting Research Tool
...
Chapter 3 — Measuring Significance

3.1 The Significance Tests

3.1 The Significance Tests

Rules 3-09, 4-08(g), 8-03(b)(3),1 and 10-01(b)(1) require registrants to evaluate the significance of an equity method investment in accordance with the tests in Rule 1-02(w).

Footnotes

1
See Section 2.5 for a discussion of the SEC reporting requirements for SRCs under Rule 8-03.
2
The annual financial statements of a significant equity method investee must be audited for the periods in which one of the applicable significance tests exceeds 20 percent. The financial statements may be unaudited for periods in which the equity method investee is not significant.
3
A registrant may be required to use income averaging in accordance with paragraph 2015.8 of the FRM regardless of whether it reports income or loss in its most recent annual period. See Section 3.1.3.3 for more information about how a registrant should use average income when performing the income test.
4
See Section 3.1.3.1 for guidance on determining the numerator of the income component under Rule 3-09.
6
See Section 3.1.3.1 for guidance on performing the income test for equity method investees under Rule 3-09.
8
See Section 3.1.3.1 for guidance on determining whether any adjustments to the numerator are required for other amounts related to the equity method investee that are recorded directly by the registrant (such as impairment charges and preferred stock dividends).
9
If either the registrant or the equity method investee incurred a pretax loss from continuing operations in the fiscal year used to perform the income test, the registrant should use the absolute value of this loss when performing the income test. See Section 3.1.3.4 for further discussion about performing the income test when the registrant or the equity method investee has a loss in the fiscal year.
10
This excludes the investee’s pretax loss from the denominator because the investee had a pretax loss while the registrant had pretax income. See further discussion in Section 3.1.3.4.
11
See footnote 8.
12
See footnote 9.
13
See footnote 8.
14
See footnote 9.